🔗 Share this article

An underground economy for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Experimental Drug Acquiring Popularity Online

Retatrutide, which is still in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Viewers are urged to message these accounts privately for supplier links, while also obtaining discount codes.

Active Trade on Messaging Platforms

Separately, a flourishing trade exists on Telegram, where communities with thousands of members share “before and after” images, injection guides and assertions of rapid UK delivery. Sellers market the drug there before directing buyers to other platforms for purchases.

Learning About Retatrutide

This medication is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Professionals Voice Worries

Nevertheless, physicians and pharmacists have warned that the distribution of what remains an unlicensed medication in the UK is a cause for concern and could lead to users injecting substances of uncertain source.

Some professionals stated the popularity for retatrutide could be linked to the increasing cost of approved weight loss treatments such as Mounjaro.

Legal Status and Enforcement

Selling the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unlicensed medication that must not be marketed or distributed for human use under the British medical regulations.

Some content creators attempt to sidestep the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still violate medicines, marketing, and consumer laws, risking fines, prosecution or imprisonment.

Service Response and Content Removal

Based on the social media company, the service has taken down problematic content and prohibited related keywords and query recommendations. The organization stated it was committed to maintaining the platform safe and investing in strengthening enforcement strategies.

Digital Marketplace Operations

Research also found groups with up to 9,000 participants selling retatrutide using Telegram's integrated search feature, which functions like a public directory. Entering “retatrutide” immediately displays groups with thousands of users, filled with images of weight loss, positive testimonials and step-by-step guides for mixing or injecting at home.

After moments of entering one community, a seller posted contact information, where the majority of transactions occur. The seller provided an instruction manual and promised shipping within two days. When questioned whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one inquired about weight, health issues or past usage.

Item Details and Costs

Within these groups, messages display black plastic parcels with Royal Mail stickers, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at residence with purified liquid, or pre-filled injectors usually sold at 160 pounds for 20 milligrams. When asked how long a injector should be used, sellers give contradictory answers varying between a few weeks to “depends on your body”.

Platform Moderation and Security Actions

A representative for Telegram said it regularly moderated dangerous content on its platform including content that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they cannot confirm. Even if the research behind this drug is sound, these digital versions may not include what they claim,” said a pharmacy expert, the head of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor linked the increase in interest to recent price rises for authorized slimming medications such as Mounjaro. “With prices rising, individuals are using social media. But fake injections are highly dangerous. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she said.

Her staff has previously seen patients injured by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” said Wyllie. “These materials could be impure or improperly measured.”

Producer Position

A spokesperson from Eli Lilly stated retatrutide was in third stage clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a company experimental product not yet approved … may subject users to possibly significant medical dangers”.